IL6 and breast cancer: However, the AUC was 0.801 (95% CI: 0.699-0.903, p-value < 0.001), sensitivity was 83.3%, and specificity was 73.3% when IL-6, IL-17, and VEGF were combined for diagnosis, therefore, serum levels of IL-6, IL-17 and VEGF are associated with the development and progression of breast cancer, and combined monitoring of the above cytokines seems to have clinical application for the early diagnosis of breast cancer patients.